AZD 5718

Drug Profile

AZD 5718

Alternative Names: AZD5718

Latest Information Update: 26 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Cardiovascular therapies; Small molecules
  • Mechanism of Action 5-lipoxygenase activating protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coronary artery disease
  • Phase I Cardiovascular disorders

Most Recent Events

  • 12 Jun 2018 AstraZeneca completes a phase I trial in Coronary artery disease (In volunteers) in USA (PO) (NCT03400488)
  • 18 Apr 2018 AstraZeneca in collaboration with Parexel completes a phase I trial in Coronary artery disease (In volunteers) in United Kingdom (PO) (NCT03420092)
  • 09 Feb 2018 AstraZeneca and Parexel plans a phase I trial for Coronary artery disease (In volunteers) in United Kingdom in February 2018 (NCT03420092)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top